Trial Profile
A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Tamsulosin
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms Match
- Sponsors Astellas Pharma
- 27 Nov 2020 Results of post hoc analysis of efficacy from MATCH trial published in the Advances in Therapy
- 26 Jul 2020 Results (n=56) comparing efficacy of mirabegron 50 mg addition after alpha-blocker, presented at the 35th Congress of the European Association of Urology.
- 26 Jul 2020 Results of post-hoc analyses of efficacy presented at the 35th Congress of the European Association of Urology